Four-week studies of oral hypoxia-inducible factor–prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia

Journal of the American Society of Nephrology

Volumn 27, Issue 4, 2016, Pages 1234-1244

  Holdstock, Louis ^a   Meadowcroft, Amy M ^a   Maier, Rayma ^b   Johnson, Brendan M ^a   Jones, Delyth ^b   Rastogi, Anjay ^c   Zeig, Steven ^d   Lepore, John J ^a   Cobitz, Alexander R ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Pines Care Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPRODUSTAT; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VASCULOTROPIN; BARBITURIC ACID DERIVATIVE; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE;

AGED; ANEMIA; ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; IRON BINDING CAPACITY; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; SINGLE BLIND PROCEDURE; TIME FACTOR;

AGED; ANEMIA; BARBITURATES; ERYTHROPOIETIN; FEMALE; GLYCINE; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 85016924015     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/asn.2014111139     Document Type: Article

References (49)

1. Vaziri ND, Zhou XJ: Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24: 1082–1088, 2009
2. Babitt JL, Lin HY: Mechanisms of anemia in CKD. J Am Soc Nephrol 23: 1631–1634 2012
3. Nurko S: Anemia in chronic kidney disease: Causes, diagnosis, treatment. Cleve Clin J Med 73: 289–297, 2006
4. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279–335, 2012
5. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63: 713–735, 2014
6. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R; Anaemia Working Group of European Renal Best Practice (ERBP): Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 25: 2846–2850, 2010
7. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: ii1–ii47, 2004
8. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T: 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 14: 240–275, 2010
9. Besarab A, Coyne DW: Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6: 699–710, 2010
10. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A: Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev (3): CD003266, 2005
11. Foley RN, Curtis BM, Parfrey PS: Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: A randomized trial. Clin J Am Soc Nephrol 4: 726–733, 2009
12. Valliant A, Hofmann RM: Managing dialysis patients who develop anemia caused by chronic kidney disease: Focus on peginesatide. Int J Nanomedicine 8: 3297–3307, 2013
13. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098, 2006
14. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084, 2006
15. Singh AK: Lessons from TREAT: Lower hemoglobin target, avoid ESA if possible. Nephrol Times 2: 6–7, 2009
16. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019–2032, 2009
17. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. Kidney Int 74: 791–798, 2008
18. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJV, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146–1155, 2010
19. Johnson BM, Stier BA, Caltabiano S: Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clin Pharmacol Drug Devel 3: 109–117, 2013
20. Del Vecchio L, Locatelli F: Anemia in chronic kidney disease patients: Treatment recommendations and emerging therapies. Expert Rev Hematol 7: 495–506, 2014
21. Haase VH: Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 27: 41–53, 2013
22. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C: HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 119: 1159–1166, 2009
23. Ding H, Yan CZ, Shi H, Zhao YS, Chang SY, Yu P, Wu WS, Zhao CY, Chang YZ, Duan XL: Hepcidin is involved in iron regulation in the is-chemic brain. PLoS One 6: e25324, 2011
24. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I: The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 22: 70–77, 2009
25. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS: Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117: 1926–1932, 2007
26. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ, Tisdale JF: HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110: 2140–2147, 2007
27. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU: Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151–2156, 2010
28. Chinta SJ, Rajagopalan S, Ganesan A, Andersen JK: A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: Implications for use as a therapeutic for Parkinson’s disease. Parkinsons Dis 2012: 364684, 2012
29. Tuley RP, Gonzalez NC, Holloway NB, Blanco VG, Casillan AJ, West CE, Michael M, Thomas JH, Wood JG: Prolyl hydroxylase inhibition attenuates hypoxia-induced microvascular inflammation via iNOS upre-gulation [Abstract]. FASEB J 22[Suppl]: 731.2, 2008
30. Walmsley SR, Chilvers ER, Thompson AA, Vaughan K, Marriott HM, Parker LC, Shaw G, Parmar S, Schneider M, Sabroe I, Dockrell DH, Milo M, Taylor CT, Johnson RS, Pugh CW, Ratcliffe PJ, Maxwell PH, Carmeliet P, Whyte MK: Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. J Clin Invest 121: 1053–1063, 2011
31. Brigandi RA, Johnson B, Oei C, Westerman ME, Olbina G, Kumar S, Russ SF: Induction of erythropoiesis in anemic patients by prolylhy-droxylase inhibitor in a repeat dose, randomized placebo controlled trial [Abstract]. J Am Soc Nephrol 23[Suppl]: 662A, 2012
32. Besarab A, Provenzano R, Fishbane S, Sun CH, Belo DS, Neff TB, Lee TT, Franco M, Leong R, Yu KHP: Oral hypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron [Abstract]. J Am Soc Nephrol 22[Suppl]: 196A, 2011
33. Brigandi RA, Russ SF, Oei C, Westerman ME, Olbina G, Hodsman P, Kumar S: Modulation of erythropoietin by prolyl hydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [Abstract]. J Am Soc Nephrol 22[Suppl]: 203A, 2011
34. McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M: Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3: 1006–1014, 2008
35. Yapa SWS, Johnson BM, Ravindranath R, Caltabiano S, Cobitz AR: Steady-state pharmacokinetics of GSK1278863 and metabolites in subjects with normal and impaired renal function [Abstract]. Clin Pharmacol Ther 97[Suppl 1]: S92, 2015
36. Mason-Garcia M, Beckman BS, Brookins JW, Powell JS, Lanham W, Blaisdell S, Keay L, Li SC, Fisher JW: Development of a new radioim-munoassay for erythropoietin using recombinant erythropoietin. Kidney Int 38: 969–975, 1990
37. Piperno A, Galimberti S, Mariani R, Pelucchi S, Ravasi G, Lombardi C, Bilo G, Revera M, Giuliano A, Faini A, Mainini V, Westerman M, Ganz T, Valsecchi MG, Mancia G, Parati G; HIGHCARE investigators: Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: Data from the HIGHCARE project. Blood 117: 2953–2959, 2011
38. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590, 1998
39. Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, Porto G: Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 111: 5727–5733, 2008
40. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FWK, Chapman RS, Maxwell PH, Choi P: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75: 976–981, 2009
41. Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y: Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol 96: 692–700, 2012
42. Lakhal S, Schödel J, Townsend ARM, Pugh CW, Ratcliffe PJ, Mole DR: Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: New link between hypoxia signaling and iron homeostasis. J Biol Chem 286: 4090–4097, 2011
43. Mastrogiannaki M, Matak P, Mathieu JRR, Delga S, Mayeux P, Vaulont S, Peyssonnaux C: Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 97: 827–834, 2012
44. Karuppagounder SS, Ratan RR: Hypoxia-inducible factor prolyl hydroxylase inhibition: Robust new target or another big bust for stroke therapeutics? J Cereb Blood Flow Metab 32: 1347–1361, 2012
45. Nitta K, Uchida K, Kimata N, Honda K, Kobayashi H, Kawashima A, Yumura W, Nihei H: Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. Eur J Pharmacol 373: 121–124, 1999
46. Goel HL, Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer 13: 871–882, 2013
47. Pullar T, Kumar S, Tindall H, Feely M: Time to stop counting the tablets? Clin Pharmacol Ther 46: 163–168, 1989
48. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145: 247–254, 2006
49. World Medical Association: WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available at http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed August 20, 2013